Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...

Novavax stock (NVAX) skyrocketed Friday ... While Novavax's vaccine did finally reach the market in mid-2022, targeting the booster market, it continued to struggle with $1.7 billion in ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Short interest in Novavax Inc (NASDAQ:NVAX) increased during the last reporting period, rising from 35.45M to 39.23M. This put 30.38% of the company's publicly available shares short. Short ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported a loss of $81 million in its fourth quarter. On a per-share basis, the Gaithersburg, Maryland-based ...